SANTA CRUZ BIOTECHNOLOGY, INC.

HLA-C (C-8): sc-166088

SANTA CRUZ BIOTECHNOLOGY

The Power to Question

BACKGROUND

Major histocompatibility complex (MHC) class II molecules destined for presentation to $CD4^+$ helper T cells is determined by two key events. These events include the dissociation of class II-associated invariant chain peptides (CLIP) from an antigen binding groove in MHC class IIa/b dimers through the activity of MHC molecules HLA-DM and -DO, and subsequent peptide antigen binding. Accumulating in endosomal/lysosomal compartments and on the surface of B cells, HLA-DM, -DO molecules regulate the dissociation of CLIP and the subsequent binding of exogenous peptides to HLA class II molecules (HLA-DR, -DQ and -DP) by sustaining a conformation that favors peptide exchange. RFLP analysis of HLA-DM genes from rheumatoid arthritis (RA) patients suggests that certain polymorphisms are genetic factors for RA susceptibility. HLA-B belongs to the HLA class I heavy chain paralogs. Class I molecules play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum lumen. HLA-B and -C can form heterodimers consisting of a membrane anchored heavy chain and a light chain (β-2-Microglobulin). Polymorphisms yield hundreds of HLA-B and -C alleles.

CHROMOSOMAL LOCATION

Genetic locus: HLA-C (human) mapping to 6p21.33.

SOURCE

HLA-C (C-8) is a mouse monoclonal antibody specific for an epitope mapping between amino acids 91-123 within an internal region of HLA-C of human origin.

PRODUCT

Each vial contains 200 µg IgG_1 kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

HLA-C (C-8) is available conjugated to agarose (sc-166088 AC), 500 µg/0.25 ml agarose in 1 ml, for IP; to HRP (sc-166088 HRP), 200 µg/ml, for WB, IHC(P) and ELISA; to either phycoerythrin (sc-166088 PE), fluorescein (sc-166088 FITC), Alexa Fluor® 488 (sc-166088 AF488), Alexa Fluor® 546 (sc-166088 AF546), Alexa Fluor® 594 (sc-166088 AF594) or Alexa Fluor® 647 (sc-166088 AF647), 200 µg/ml, for WB (RGB), IF, IHC(P) and FCM; and to either Alexa Fluor® 680 (sc-166088 AF680) or Alexa Fluor® 790 (sc-166088 AF790), 200 µg/ml, for Near-Infrared (NIR) WB, IF and FCM.

Blocking peptide available for competition studies, sc-166088 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% stabilizer protein).

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

APPLICATIONS

HLA-C (C-8) is recommended for detection of HLA-C of human origin by Western Blotting (starting dilution 1:100, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for HLA-C siRNA (h): sc-105525, HLA-C shRNA Plasmid (h): sc-105525-SH and HLA-C shRNA (h) Lentiviral Particles: sc-105525-V.

Molecular Weight of HLA-C: 43 kDa.

Positive Controls: HeLa whole cell lysate: sc-2200, U266 whole cell lysate: sc-364800 or HLA-C (h): 293 Lysate: sc-159324.

RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use m-IgGκ BP-FITC: sc-516140 or m-IgGκ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz® Mounting Medium: sc-24941 or UltraCruz® Hard-set Mounting Medium: sc-359850.

DATA



HLA-C (C-8) Alexa Fluor® 488: sc-166088 AF488. Direct fluorescent western blot analysis of HLA-C expression in HeLa (**A**), CCRF-CEM (**B**), U266 (**C**) and A-431 (**D**) whole cell lysates and human skin tissue extract (**E**). Blocked with UltraCruz® Blocking Reagent: sc-516214.



HLA-C (C-8): sc-166088. Western blot analysis of HLA-C expression in non-transfected 293: sc-110760 (**A**), human HLA-C transfected 293: sc-159324 (**B**) and HeLa (**C**) whole cell lysates.

SELECT PRODUCT CITATIONS

1. Pesce, S., et al. 2015. Uptake of CCR7 by $KIR2DS4^+$ NK cells is induced upon recognition of certain HLA-C alleles. J. Immunol. Res. 2015: 754373.
2. Arakawa, A., et al. 2021. ERAP1 controls the autoimmune response against melanocytes in psoriasis by generating the melanocyte autoantigen and regulating its amount for HLA-C*06:02 presentation. J. Immunol. 207: 2235-2244.

RESEARCH USE

For research use only, not for use in diagnostic procedures.